Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005044 · ClinicalTrials.gov registry record · Phase 3
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,579
- Enrollment target
NCT00005044: Completed Phase 3 study, sponsored by Radiation Therapy Oncology Group.
NCT00005044 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 1,579 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (105% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005044, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,579 participants
- Enrollment target
Study Summary
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer.
Primary Outcome
Disease-specific survival time is measured from date of randomization to death due to prostate cancer based on study chair review, with prostate-cancer death defined as (1) primary cause of death certified as due to prostate cancer, (2) complication of therapy, irrespective of disease status, (3) disease progression in the absence of any anti-tumor therapy, or (4) a 1.0 ng/ml-exceeding-rise in serum prostate-specific antigen (PSA) level on at least two consecutive occasions that occurs during or
Interventions
- DRUG LHRH agonist
- RADIATION radiation therapy
- DRUG Casodex
- DRUG Eulexin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,579 participants |
| Start Date | 2000-02 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 3 |
What the finished NCT00005044 record still lists
NCT00005044 is an interventional study that assigns participants to a tested intervention. Its 1,579 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (105% higher).
The record links to 0 conditions, and to 4 interventions - of which LHRH agonist is the first listed.
NCT00005044 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005044 about?
NCT00005044 is a clinical study titled "Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is mor...
What is the current status of trial NCT00005044?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,579 participants. The study started on 2000-02. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT00005044?
The interventions under investigation include: LHRH agonist (DRUG), radiation therapy (RADIATION), Casodex (DRUG), Eulexin (DRUG).
Who is sponsoring clinical trial NCT00005044?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00005044's enrollment target sits among peer trials
1,579 149th of 2000 higher than 1,852 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05483855 · 1,580 participants
Telehealth-delivered HealthcaRe to ImproVe Care
- NCT06445946 · 1,572 participants · Phase 4
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia